Search Results for "Heart Failure"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Heart Failure. Results 201 to 210 of 276 total matches.
Ertugliflozin for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Apr 23, 2018 (Issue 1545)
with an eGFR ...
The FDA has approved the sodium-glucose co-transporter
2 (SGLT2) inhibitor ertugliflozin (Merck)
for treatment of adults with type 2 diabetes, both
alone (Steglatro) and in fixed-dose combinations
with metformin (Segluromet) and sitagliptin
(Steglujan). Ertugliflozin is the fourth SGLT2 inhibitor
to be approved in the US. All four are available in
combination with metformin and three are available
in combination with a dipeptidyl peptidase-4 (DPP-4)
inhibitor (see Table 3).
IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
conduction disorders, or heart failure. Use of the drug
should be avoided in patients with congenital long ...
The FDA has approved IV amisulpride (Barhemsys –
Acacia), a selective dopamine-2 and -3 (D2/D3) receptor
antagonist, for prevention and treatment of postoperative
nausea and vomiting (PONV) in adults. It is the first
antiemetic to be approved for rescue treatment of
PONV in patients who have symptoms despite receiving
antiemetic prophylaxis. Oral formulations of amisulpride
are available in Europe for treatment of schizophrenia
and acute psychotic episodes.
Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes (online only)
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024 (Issue 1708)
-site reactions
▶ Increased heart rate
▶ Renal impairment and acute renal failure
▶ Possible ...
View the Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e1-3 doi:10.58347/tml.2024.1708c | Show Introduction Hide Introduction
Clenpiq - A Low-Volume Sodium Picosulfate-Based Colonoscopy Preparation
The Medical Letter on Drugs and Therapeutics • May 21, 2018 (Issue 1547)
with heart failure, renal
impairment, or electrolyte disturbances is unknown.
Sodium phosphate tablets ...
The FDA has approved Clenpiq (Ferring), a low-volume
oral solution that contains sodium picosulfate,
magnesium oxide, and anhydrous citric acid, for colon
cleansing prior to colonoscopy in adults. The ready-to-drink
solution contains the same ingredients as Prepopik,
which is supplied as a powder for reconstitution.
Drugs of Choice for Cancer
Treatment Guidelines from The Medical Letter • Mar 01, 2003 (Issue 7)
erythrodysesthesia; conjunctivitis; heart failure; seizures
Flutamide (Eulexin – Schering; Nausea; diarrhea; hot ...
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer...
Pipecuronium - A New Neuromuscular Blocker
The Medical Letter on Drugs and Therapeutics • Dec 14, 1990 (Issue 833)
patients and in those with renal failure (JE Caldwell et al, Anesthesiology, 70:7, 1989). The advantage ...
Pipecuronium bromide (Arduan - Organon), a long-acting, non-depolarizing neuromuscular agent chemically related to pancuronium (Pavulon; and others), is now available in the USA for use as a skeletal muscle relaxant during general anesthesia and for endotracheal intubation. It is not recommended for procedures that last less than 90 minutes or for patients requiring prolonged mechanical ventilation in intensive care units.
Drugs for Inflammatory Bowel Disease
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
reactions, new-onset psoriasis, cytopenias, nonischemic
congestive heart failure, demyelinating
disorders ...
Ulcerative colitis (UC) and Crohn's disease (CD),
referred to collectively as inflammatory bowel disease
(IBD), are chronic immune-mediated inflammatory
conditions. Guidelines for treatment of UC and CD
have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12 doi:10.58347/tml.2023.1680a | Show Introduction Hide Introduction
Substituting For Cerivastatin (Baycol)
The Medical Letter on Drugs and Therapeutics • Sep 17, 2001 (Issue 1113)
in creatinine kinase, rarely progressing to rhabdomyolysis, myoglobinemia and renal failure, have occurred ...
Full-page newspaper advertisements are urging patients with high cholesterol levels who are stopping Baycol (cerivastatin) to ask their doctors about Pravachol (pravastatin), Lipitor (atorvastatin), Zocor (simvastatin) or Lescol (fluvastatin). Some advertisements come with a coupon for free medication. Lovastatin, which is available generically, has not appeared in similar advertisements. Cerivastatin was withdrawn from the market on August 8 because of post-marketing reports of 31 cases of fatal rhabdomyolysis.
In Brief: Casgevy for Beta Thalassemia
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
thalassemia.
THE DISORDER — Beta thalassemia can cause severe
anemia, fatigue, shortness of breath, failure ...
Exagamglogene autotemcel (Casgevy – Vertex), a cell-based
gene therapy recently approved for treatment
of sickle cell disease1, has now been approved by
the FDA for treatment of patients ≥12 years old with
transfusion-dependent beta thalassemia. Casgevy is
the first gene therapy that uses CRISPR/Cas9 gene-editing
technology to be approved in the US for any
disorder. Betibeglogene autotemcel (Zynteglo), an
autologous lentiviral vector cell-based gene therapy,
was approved in the US in 2022 for treatment of
transfusion-dependent beta thalassemia.
Med Lett Drugs Ther. 2024 May 13;66(1702):79 doi:10.58347/tml.2024.1702d | Show Introduction Hide Introduction
A Percutaneous Device (MitraClip) for Mitral Regurgitation
The Medical Letter on Drugs and Therapeutics • Dec 23, 2013 (Issue 1432)
regurgitation,
but it generally involves open heart surgery and
cardiopulmonary bypass and can cause ...
The FDA has approved the use of a transcatheter
mitral valve device (MitraClip – Abbott) for percutaneous
treatment of significant symptomatic degenerative
mitral regurgitation (grade 3-4+) in patients who
are at prohibitive risk for mitral valve surgery. It is the
first percutaneous nonsurgical treatment approved for
this indication.